Printer Friendly

NABI AWARDED $7 MILLION NAVY TESTING CONTRACT

 NABI AWARDED $7 MILLION NAVY TESTING CONTRACT
 MIAMI, Aug. 17 /PRNewswire/ -- North American Biologicals, Inc.


("NABI") (NASDAQ: NBIO) today announced it has received a three-year HIV testing contract, valued at approximately $7 million, from the United States Navy. NABI has been conducting HIV testing for the Navy since 1989 under a similar contract, which expires this month.
 "NABI has emerged in recent years as one of the leaders in the field of AIDS testing, which is still the most effective measure for early diagnosis and treatment," said David J. Gury, NABI's chairman, president and CEO. "As a part of our testing business, we will continue to develop quality control products and testing services that contribute to the overall national effort to eradicate this disease."
 The Naval contract involves testing for new personnel, periodic testing of existing personnel, and testing for personnel relocating overseas. Tests are conducted at NABI's testing laboratory in Miami and results are reported to the Bethesda Naval Hospital.
 North American Biologicals, Inc. is the world's largest independent provider of human blood plasma elements to the health care industry. The company collects, processes, tests and distributes human blood- related products, manufactures and markets plasma/sera-based diagnostic products and markets clinical diagnostic testing services.
 -0- 8/17/92
 /CONTACT: David J. Gury, president, or Alfred J. Fernandez, VP finance, North American Biologicals, 305-628-0880; or Lori E. Martin, Feinstein Partners, 617-577-8110, for North American Biologicals, Inc./
 (NBIO) CO: North American Biologicals, Inc. ST: IN: MTC SU: CON


CH -- NE006 -- 0499 08/17/92 12:09 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1992
Words:256
Previous Article:THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
Next Article:FANNIE MAE DEBENTURE REDEMPTION
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS TO ACQUIRE INTERNATIONAL BIOLOGICALS BUSINESS AND ALL OUTSTANDING STOCK HELD BY ITS CONTROLLING SHAREHOLDER
RAYTHEON DIVISION TO ASSIST DISADVANTAGED VIRGINIA FIRM
NORTH AMERICAN BIOLOGICALS AWARDED $9 MILLION IN FEDERAL CONTRACTS FOR AIDS SCREENING AND OTHER BLOOD TESTING AND PRODUCTS
NORTH AMERICAN BIOLOGICALS ARRANGES $19.5 MILLION IN FINANCING FOR ACQUISITION AND STOCK REPURCHASE
FDA CLEARS NABI'S QC-HEPATITIS PRODUCT FOR MARKETING
WYLE LABORATORIES WINS $7 MILLION NAVY CONTRACT
NORTH AMERICAN BIOLOGICALS, INC. AWARDED $45 MILLION EUROPEAN CONTRACT: PLASMA ORDER IS LARGEST IN NABI'S HISTORY
THERMOTREX RECEIVES $3.5 MILLION IN ADDITIONAL FUNDING TO UPGRADE LASER RADAR TRACKING SYSTEM
NORTH AMERICAN BIOLOGICALS, INC. AWARDED $165 MILLION MULTI-YEAR PLASMA SUPPLY CONTRACT
NABI to Report Non-Recurring Charge for Third Quarter 1996

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters